Objectives
We assess the effect of coronavirus disease 2019 (COVID‐19) on lower urinary tract symptoms (LUTS) of patients with benign prostatic hyperplasia (BPH). Moreover, we delineate risk factors for urine retention in such patients.
Methods
All COVID‐19 infected males were expeditiously evaluated. All enrolled patients were assessed using the International Prostate Symptom Score (IPSS), uroflowmetry, and pelvi‐abdominal ultrasonography for prostate volume and postvoiding residual urine (PVR) estimation.
Results
Fifty patients, who were diagnosed with BPH, were enrolled. The mean age (±SD) was 62.64 ± 7.69. In the pre‐ and post‐COVID‐19 group, the mean (±SD) IPSS was 13.42 ± 4.32 and 26.62 ± 5.77, respectively (P < .001), while PVR was 90.40 ± 32.75 and 185.42 ± 73.42, respectively (P < .001), and maximum flow rate was 14.40 ± 2.75 and 10.74 ± 3.43, respectively (P < .004). After infection with COVID‐19, 13 (26%) patients were managed by urethral catheter fixation owing to urine retention. On bivariate analysis, age, diabetes, large prostate on digital rectal examination, alpha‐blocker monotherapy, microscopic hematuria, positive urine culture, and pre‐COVID‐19 IPSS were significantly correlated with urine retention (P < .001, P = .01, P < .001, P = .06, P < .001, P = .04, and P < .001, respectively). On multivariate analysis, age, pre‐COVID‐19 IPSS, and positive urine culture were the independent predictors of urine retention (P = .05, P < .001, and P = .01, respectively).
Conclusion
LUTS in BPH patients were significantly affected by COVID‐19. COVID‐19 increases IPSS leading to a change in the treatment modality of BPH. On multivariate analysis, age, pre‐COVID‐19 IPSS, and positive urine culture were the independent predictors of urine retention post COVID‐19 infection.
